Avadel Pharmaceuticals (AVDL) Cash & Current Investments (2016 - 2022)
Historic Cash & Current Investments for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $106.5 million.
- Avadel Pharmaceuticals' Cash & Current Investments fell 4120.42% to $106.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $106.5 million, marking a year-over-year decrease of 4120.42%. This contributed to the annual value of $157.2 million for FY2021, which is 2898.84% down from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Cash & Current Investments stood at $106.5 million, which was down 4120.42% from $104.1 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Cash & Current Investments high stood at $238.6 million for Q2 2020, and its period low was $64.2 million during Q4 2019.
- Moreover, its 5-year median value for Cash & Current Investments was $125.3 million (2018), whereas its average is $144.8 million.
- In the last 5 years, Avadel Pharmaceuticals' Cash & Current Investments tumbled by 5970.78% in 2019 and then skyrocketed by 24508.87% in 2020.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Cash & Current Investments stood at $99.9 million in 2018, then tumbled by 35.79% to $64.2 million in 2019, then skyrocketed by 245.09% to $221.4 million in 2020, then fell by 28.99% to $157.2 million in 2021, then tumbled by 32.28% to $106.5 million in 2022.
- Its Cash & Current Investments stands at $106.5 million for Q3 2022, versus $104.1 million for Q2 2022 and $123.5 million for Q1 2022.